Figure 2. LOX-1+ PMN-MDSCs from NPC survivors with CHB and from patients with CHB suppressed T cell proliferation and activation. CD3+ T cells from PBMCs were labeled with CFSE, stimulated with anti-CD3 and anti-CD28, and then cocultured with LOX-1+ PMN-MDSCs or LOX-1- PMN from the same donors at different ratios for 3 days. CD4+ and CD8+ T cell proliferation was evaluated by CFSE labeling and IFN-γ production in supernatants by ELISA. (A) T cells receiving no anti-CD3/anti-CD28 stimulation were used as negative controls with stimulated T cells without the addition of LOX-1+ PMN-MDSC/PMN as a positive control. (B) The influence of LOX-1+ PMN-MDSCs or LOX-1- PMN from NPC survivors with CHB on T cell proliferation was displayed by representative of one independent experiment, cumulative data, and concentration of IFN-γ in the media. (C) The influence of LOX-1+ PMN-MDSCs or LOX-1- PMN from CHB patients on T cell proliferation was shown by representative of one independent experiment, cumulative data, and concentration of IFN-γ in the media. (Comparison was made between the 1:0 group and experimental groups), (n = 4 in each group) *, P < 0.05; **, P < 0.01; ***, P < 0.001. Abbreviations: PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; NPC, nasopharyngeal carcinoma; CHB, chronic hepatitis B; PBMC, peripheral blood mononuclear cells; PMN, polymorphonuclear cell; CFSE, 5,6-carboxyfluoresceindiacetate, succinimidylester; IFN, interferon.